Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P675 CT-Scout platform, the digital solution to boost patient recruitment in inflammatory bowel disease clinical trials: A multicentre prospective observational comparative study

ECCO'20 Vienna

Year: 2020
Authors:

Y. Bouhnik1, X. Hebuterne2, M. Raith3, A. Amiot4, C. Tanasa Stefanescu1, D. Laharie5, X. Roblin6, A. Bourreille7, S. Nancey8, N. Sabbah9, L. Peyrin Biroulet10

1Hopital Beaujon, Service de Gastroentérologie,MICI et Assistance Nutritive, Clichy, France, 2Hopital Archet, Service de Gastroentérologie et Nutrition Clinique, Nice, France, 3CTMA, Project Manajer, Paris, France, 4Hopital Henri Mondor, Service de Gastroentérologie, Creteil, France, 5Hopital Haut-Léveque, Service d’Hépato-Gastroentérologie, Bordeaux, France, 6Hopital Bellevue, Service de Gastroentérologie, Saint Etienne, France, 7CHU Hotel-Dieu, Institut des maladies de l’appareil digestif, Nantes, France, 8Hopital Lyon Sud, Service d’hépatogastroentérologie, Lyon, France, 9CTMA, Chief Operating Officier, Paris, France, 10CHU Nancy, Hépato-Gastro-Entérologie, Nancy, France

P676 Faecal monitoring is useful in monitoring treatment response in anti-TNF-treated patients

ECCO'20 Vienna

Year: 2020
Authors:

K. Farkas1, K.J. Szántó1, D. Kata2, I. Földesi2, T. Ferenci3, M. Rutka1, D. Pigniczki1, R. Bor1, A. Fábián1, Z. Szepes1, F. Nagy1, T. Molnár1

1First Department of Medicine, University of Szeged, Szeged, Hungary, 2Department of Laboratory Medicine, University of Szeged, Szeged, Hungary, 3Physiological Controls Research Center, Óbuda University, Szeged, Hungary

P677 It’s time to grow up: what is it like to transition from the paediatric to adult inflammatory bowel disease service?

ECCO'20 Vienna

Year: 2020
Authors:

P. Keightley1,2, R. Prematunga1, P. Hoffmann3, K. Subramaniam2,4

1Canberra Health Services, Mental Health, Justice Health, Alcohol and Drug Services, Canberra, Australia, 2Australian National University, Australian National University Medical School, Canberra, Australia, 3Canberra Health Services, Acute Allied Health Psychology Department, Canberra, Australia, 4Canberra Hospital, Gastroenterology and Hepatology Unit, Canberra, Australia

P678 Effect of accelerated infliximab induction on short-term outcomes of paediatric acute severe ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

M.B. Coronel-Arismendi, G. Pujol Muncunill, B. Minguez-Rodríguez, S. Feo-Ortego, L.N. Guevara-Caviedes, V. Vila-Miravet, F.J. Martin De Carpi

Hospital Sant Joan de Déu, Unit for the Comprehensive Care of Pediatric Inflammatory Bowel Disease, Department of Pediatric Gastroenterology, Hepatology and Nutrition, Esplugues de Llobregat, Spain

P679 What is the best strategy after failure to anti-TNF? Ustekinumab or other anti-TNF?

ECCO'20 Vienna

Year: 2020
Authors:

A. Cerpa Arencibia, C. Suarez Ferrer, J. Poza Cordón, E. Martín Arranz, L. Ramírez, M.D. Martín Arranz

Hospital La Paz, Gastroenterology, Madrid, Spain

P681 Efficacy of vedolizumab for the prevention of postoperative recurrence in Crohn’s disease: Data from clinical practice from the ENEIDA registry

ECCO'20 Vienna

Year: 2020
Authors:

M. Mañosa Ciria1, E. Hinojosa2, A. Carbajo3, J. Castro4, N. Manceñido5, M. Calvo6, A. Núñez Alonso7, J. P Gisbert8, P. Nos9, J. Guardiola10, E. Sainz11, E. Sánchez-Rodríguez12, F. Cañete1, M. Calafat1, E. Domènech1, Eneida Registry

1Hospital Universitari Germans Trias I Pujol, Department of Gastroenterology CIBERehd, IBD Unit, Badalona, Spain, 2Hospital de Manises, Gastroenterology, Manises, Spain, 3Hospital Rio Hortega, Gastroenterology, Valladolid, Spain, 4Hospital Clínic de Barcelona, Gastroenterology, Barcelona, Spain, 5Hospital Infanta Sofia, Gastroenterology, Madrid, Spain, 6Hospital Puerta de Hierro, Gastroenterology, Madrid, Spain, 7Hospital de Salamanca, Gastroenterology, Salamanca, Spain, 8Hospital La Princesa, Gastroenterology, Madrid, Spain, 9Hospital La Fe, Gastroenterology, Valencia, Spain, 10Hospital de Bellvitge, Gastroenterology, Barcelona, Spain, 11Althaia, Gastroenterology, Manresa, Spain, 12Hospital Ramon y Cajal, Gastroenterology, Madrid, Spain

P682 Faecal calprotectin and C-reactive protein levels are associated with long-term clinical and endoscopic outcomes: Analysis of the OASIS open-label extension trial of etrasimod for ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

A. Yarur1, M. Chiorean2, J. Zhang3, W. Reinisch4, S. Vermeire5, J. Panés6, L. Peyrin-Biroulet7, B.E. Sands8, C.H. Cabell3, S.U. Naik3, W.J. Sandborn9

1Medical College of Wisconsin, n/a, Milwaukee, USA, 2Virginia Mason Medical Center, n/a, Seattle, USA, 3Arena Pharmaceuticals, n/a, San Diego, USA, 4Medical University of Vienna, n/a, Vienna, Austria, 5University Hospitals Leuven, n/a, Leuven, Belgium, 6Hospital Clinic of Barcelona- DIBAPS- CIBERehd, n/a, Barcelona, Spain, 7Lorraine University, Department of Gastroenterology- INSERM U954, Vandoeuvre-lès-Nancy, France, 8Icahn School of Medicine at Mount Sinai, n/a, New York, USA, 9University of California San Diego, n/a, La Jolla, USA

P683 Infliximab, adalimumab and vedolizumab levels are not altered by pregnancy progression in IBD patients and neonatal vedolizumab levels are lower than in mothers: Results from the PICCOLO study

ECCO'20 Vienna

Year: 2020
Authors:

E. Flanagan1, P.R. GIbson2, O. Rosella3, A. Ross4, S.J. Bell4, The PICCOLO Study

1Department of Gastroenterology, St Vincent’s Hospital Melbourne, Fitzroy, Australia, 2Department of Gastroenterology, Alfred Health, Monash, Australia, 3Department of Gastroenterology, Monash University, Melbourne, Australia, 4Department of Gastroenterology, St Vincent’s Hospital Melbourne, Melbourne, Australia

P684 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: updated results from the tofacitinib ulcerative colitis clinical programme

ECCO'20 Vienna

Year: 2020
Authors:

B.E. Sands1, P.R. Taub2, B.G. Feagan3, A. Armuzzi4, A.O. Damião5, N. Lawendy6, G. Solano7, K. Kwok8, J. Woolcott6, L. Salese6, C. Su6

1Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York- NY, USA, 2Division of Cardiovascular Medicine- UC San Diego School of Medicine, La Jolla, California, USA, 3Robarts Clinical Trials- Western University, London, Ontario, Canada, 4IBD Unit- Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, 5Department of Gastroenterology, University of São Paulo USP, São Paulo, Brazil, 6Pfizer Inc., Collegeville, Pennsylvania, USA, 7Pfizer Inc., San José, Costa Rica, Costa Rica, 8Pfizer Inc., New York, New York, USA

P685 Healthcare resource use associated with ferric maltol and IV iron treatment for iron deficiency anaemia in patients with inflammatory bowel diseaseECCO'20 Vienna
Year: 2020
Authors: S. Howaldt1, I. Jacob2, M. Sampson3, F. Akriche4

1MZV für Immunologie, Gastroenterology, Hamburg, Germany, 2Health Economics and Outcomes Research Ltd., Health economics, Cardiff, UK, 3Shield Therapeutics PLC, Medical, London, UK, 4Norgine Ltd., Medical, Rueil Malmaison, France

Corrigendum:

In the originally published version of this poster presentation, the below corrections have been made.

Upon the original publication, the following sentence in Results section should read: “The primary endpoint was not met.” instead of “The non-inferiority endpoint was met.”.

Upon the original publication, the final concluding remarks should read: “FM is associated with substantially lower HCRU than IV FCM, and may provide a cost-effective oral alternative to IV iron in patients with IBD.” instead of “FM is associated with non-inferior efficacy and substantially lower HCRU than IV FCM, and may provide a cost-effective oral alternative to IV iron in patients with IBD.”.

P686 Expression of CD39 ectonucleotidase on regulatory T cells and on T helper 17 cells in children with IBD receiving anti-TNF therapy

ECCO'20 Vienna

Year: 2020
Authors:

S.V. Petrichuk1, Т. Radygina1, A. Illarionov2, D. Kuptsova1, A. Potapov3, A.P. Fisenko3

1National Medical Research Center for Children’s Health, Laboratory of Experimental Immunology and Virology, Moscow, Russian Federation, 2Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Department of Pediatrics and Rheumatology, Moscow, Russian Federation, 3National Medical Research Center for Children’s Health, Gastroenterology and Hepatology, Moscow, Russian Federation

P687 Early and sustained improvement in stool frequency and rectal bleeding following 52 weeks of mirikizumab treatment

ECCO'20 Vienna

Year: 2020
Authors:

G.R. D’Haens1, T. Hibi2, M. Ferrante3, B.R. Bhandari4, E. Berliba5, J.L. Tuttle6, T. Lissoos7, K. Krueger7, N. Morris7, V. Arora7, A.N. Naegeli7, B.G. Feagan8

1Amsterdam University Medical Centers, Inflammatory Bowel Disease Centre, Amsterdam, The Netherlands, 2Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan, 3Universitair Ziekenhuizen Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 4Delta Research Partners, n/a, Bastrop, LA, USA, 5Nicolae Testemitanu State University of Medicine, Arsenia Exploratory Medicine, Chisinau, Moldova Republic of, 6Eli Lilly and Company, Lilly Biotechnology Center, San Diego, CA, USA, 7Eli Lilly and Company, Lilly Biomedicines, Indianapolis, IN, USA, 8Western University, Robarts Clinical Trials Inc., London, ON, Canada

P688 Effect of golimumab induction therapy on histologic disease profile in patients with moderate to severe ulcerative colitis: Results from the randomised, placebo-controlled Phase 3 PURSUIT-SC trial

ECCO'20 Vienna

Year: 2020
Authors:

T. Johansson1, C. Weinstein2, A. MEEHAN3, A. Tzontcheva4, P. Xu4, C. Marano5, G. de Hertogh6

1MSD, Medical Affairs, Kriens, Switzerland, 2Merck and Co. Inc., Clinical Research, Kenilworth, USA, 3Merck and Co. Inc., Global Scientific and Medical Publications, Kenilworth, USA, 4Merck and Co. Inc., Biostatistics, Kenilworth, USA, 5Janssen Research and Development, LLC, Clinical Research, Spring House, USA, 6University Hospitals KU Leuven, Pathology, Leuven, Belgium

P689 Patient-reported outcomes (PRO-2) and intestinal ultrasound in ulcerative colitis patients: subanalysis of the TRUST&UC study cohort

ECCO'20 Vienna

Year: 2020
Authors:

C. Maaser1, U. Helwig2, I. Fischer3, S. Rath4, S. Kolterer4, T. Kucharzik5

1Hospital Lüneburg, Outpatients Department of Gastroenterology, Lüneburg, Germany, 2Gastroenterology Practice, n.a., Oldenburg, Germany, 3Biostatistik Tuebingen, n.a., Tuebingen, Germany, 4AbbVie Deutschland GmbH & Co. KG, Medical Department, Wiesbaden, Germany, 5University Teaching Hospital Lueneburg, Department of Internal Medicine and Gastroenterology, Lueneburg, Germany

P690 A propensity score weighted comparison of vedolizumab, adalimumab, and golimumab in patients with ulcerative colitis: Real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

ECCO'20 Vienna

Year: 2020
Authors:

F.S. Macaluso1, M. Ventimiglia1, W. Fries2, A. Viola2, M. Cappello3, B. Scrivo3, A. Magnano4, D. Pluchino4, S. Camilleri5, S. Garufi5, R. Di Mitri6, F. Mocciaro6, G. Magrì7, C. Ferracane7, M. Citrano8, F. Graziano8, C. Bertolami9, S. Renna1, R. Orlando1, G. Rizzuto1, M. Cottone1, A. Orlando1, Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

1A.O.O.R. ‘Villa Sofia-Cervello’, IBD Unit, Department of Medicine, Palermo, Italy, 2A.O.U. Policlinico ‘G. Martino’, Inflammatory bowel disease Unit, Messina, Italy, 3A.O.U. Policlinico ‘G. Giaccone’, Gastroenterology and Hepatology Unit, Palermo, Italy, 4A.O.U. Policlinico ‘Vittorio Emanuele’, Gastroenterology Unit, Catania, Italy, 5A.O.O.R. ‘S. Elia- M. Raimondi’, Gastroenterology Unit, Caltanissetta, Italy, 6A.R.N.A.S. ‘Civico Di Cristina Benfratelli’, Gastroenterology and endoscopy Unit, Palermo, Italy, 7A.O. ‘Santa Marta e S. Venera’, Gastroenterology Unit, Acireale, Italy, 8A.O.O.R. ‘Villa Sofia-Cervello’, Pediatrics Unit, Palermo, Italy, 9A.O.O.R. ‘Papardo Piemonte’, Gastroenterology Unit-, Messina, Italy

P691 Corticosteroids usage in patients with inflammatory bowel disease: Results of a multi-national audit in Asia

ECCO'20 Vienna

Year: 2020
Authors:

D.H. Kim1, D.I. Park2, T. Kobayashi3, V. Ahuja4, B.I. Jang5, Q. Cao6, Y.J. Lee7, Z. Ran8, Clinical Research Committee of Asian Organization for Crohn’s and Colitis (AOCC)

1Cha Bundang Medical Center, Cha University School of Medicine, Digestive Disease Center, Seongnam, Korea Republic of, 2Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea Republic of, 3Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University, Tokyo, Japan, 4Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India, 5Division of Gastroenterology and Hepatology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea Republic of, 6Department of Inflammatory Bowel Disease Center, Sir Run Run Shaw Hospital, Hangzhou, China, 7Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea Republic of, 8Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

P692 Exploring relationships between microbiome, faecal calprotectin and healthy eating index in patients with ulcerative colitis: Interim analyses of a randomised controlled trial

ECCO'20 Vienna

Year: 2020
Authors:

M. Raman1, L. Taylor1, A. Schick2, C. Ohland2, K. McCoy2, S. Kaur1, R. Panaccione1, R. Reimer3

1Department of Medicine, University of Calgary, Calgary, Canada, 2University of Calgary, Snyder, Calgary, Canada, 3Department of Kinesiology, University of Calgary, Calgary, Canada

P693 Development and evaluation of i-TRACKER infliximab and i-TRACKER anti-Infliximab kits: fast and innovative chemiluminescent assays for the monitoring of patients treated with infliximab

ECCO'20 Vienna

Year: 2020
Authors:

G. Noguier1, C. Montaillier1, S. Daviere2, L. Colombeau1, E. Parussini1

1Theradiag, Research and Development, Croissy-Beaubourg, France, 2Theradiag, Theranostics, Croissy-Beaubourg, France

P694 Validation of two commercial assays for therapeutic drug monitoring of adalimumab biosimilars

ECCO'20 Vienna

Year: 2020
Authors:

R. Berghmans1, J. Naudts2, B. Ferkinghoff3, H. Gören3, M.L. Henke3, A. Lennerz4, T. Van Stappen4

1apDia bvba, Research & Development, Turnhout, Belgium, 2apDia bvba, Marketing, Turnhout, Belgium, 3R-Biopharm AG, QM/RA Technical Validation, Darmstadt, Germany, 4R-Biopharm AG, Gastroenterology, Darmstadt, Germany